Director/PDMR Shareholding

RNS Number : 6570L

AstraZeneca PLC

10 May 2010

 



Transactions by Persons Discharging Managerial Responsibilities

Disclosure Rules DR 3.1.4R

We hereby inform you that on 7 May 2010, the following individuals, who are all persons discharging managerial responsibilities, were each granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's USD0.25 Ordinary Shares, or, in the case of L Tetrault and A Zook, over the Company's American Depositary Shares (ADSs).  One ADS equals one Ordinary Share 

Name of individual	Shares awarded under AZIP	Shares awarded under AZPSP	Award price
A Ekblom	3,949	23,698	2861p
M Pangalos	4,369	26,214	2861p
J Pott	6,000	24,903	2861p
D Smith	5,000	24,903	2861p
L Tetrault	8,097	48,585	US$42.96
A Zook	16,966	101,799	US$42.96

The AstraZeneca Investment Plan was approved by shareholders at the Company's AGM on 29 April 2010.  The awards made under this Plan on 7 May 2010 are subject to a four-year performance period and a subsequent four-year holding period.

The performance hurdle that applies to these awards relates to dividends and dividend cover. A summary of the Plan, including a more detailed explanation of the performance hurdle, can be found in the AstraZeneca Annual Report and Form 20-F Information 2009 and the Notice of AGM 2010, both of which are available on the Company's website www.astrazeneca.com.

The AstraZeneca Performance Share Plan was approved by shareholders at the Company's AGM in 2005.  Awards made under this Plan may not generally vest before the third anniversary of the relevant date of grant, nor unless the specified performance target(s) have been met at the end of the three-year performance period which, for these awards, is 1 January 2010 to 31 December 2012. 

The performance target that applies to these awards relates to relative total shareholder return and cash flow.  A summary of the Plan, including a more detailed explanation of the performance target, can be found in the AstraZeneca Annual Report and Form 20-F Information 2009 and the Notice of AGM 2010, both of which are available on the Company's website www.astrazeneca.com.

In addition to the above, M Pangalos was granted an award on 7 May 2010 under the terms of the AstraZeneca Restricted Share Plan over 24,956 ordinary shares at a price of 2861p per share. 

A C N Kemp

Company Secretary

10 May 2010

 

END

 

 

RDSURAVRROAVAAR